167 related articles for article (PubMed ID: 21900223)
1. Long-term outcomes of myeloid growth factor treatment.
Lyman GH; Dale DC
J Natl Compr Canc Netw; 2011 Aug; 9(8):945-52. PubMed ID: 21900223
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
Freedman MH; Bonilla MA; Fier C; Bolyard AA; Scarlata D; Boxer LA; Brown S; Cham B; Kannourakis G; Kinsey SE; Mori PG; Cottle T; Welte K; Dale DC
Blood; 2000 Jul; 96(2):429-36. PubMed ID: 10887102
[TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
5. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Lyman GH; Dale DC; Wolff DA; Culakova E; Poniewierski MS; Kuderer NM; Crawford J
J Clin Oncol; 2010 Jun; 28(17):2914-24. PubMed ID: 20385991
[TBL] [Abstract][Full Text] [Related]
7. Malignant myeloid transformation in congenital forms of neutropenia.
Freedman MH; Alter BP
Isr Med Assoc J; 2002 Nov; 4(11):1011-4. PubMed ID: 12489493
[TBL] [Abstract][Full Text] [Related]
8. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
9. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.
Rosenberg PS; Zeidler C; Bolyard AA; Alter BP; Bonilla MA; Boxer LA; Dror Y; Kinsey S; Link DC; Newburger PE; Shimamura A; Welte K; Dale DC
Br J Haematol; 2010 Jul; 150(2):196-9. PubMed ID: 20456363
[TBL] [Abstract][Full Text] [Related]
10. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias.
Freedman MH; Alter BP
Semin Hematol; 2002 Apr; 39(2):128-33. PubMed ID: 11957196
[TBL] [Abstract][Full Text] [Related]
11. [Indications of G-CSF administration in hematologic disorders].
Lionne-Huyghe P; Kuhnowski F; Coiteux V; Bauters F; Morschhauser F
Bull Cancer; 2006 May; 93(5):453-62. PubMed ID: 16777623
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
13. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.
Rosenberg PS; Alter BP; Bolyard AA; Bonilla MA; Boxer LA; Cham B; Fier C; Freedman M; Kannourakis G; Kinsey S; Schwinzer B; Zeidler C; Welte K; Dale DC;
Blood; 2006 Jun; 107(12):4628-35. PubMed ID: 16497969
[TBL] [Abstract][Full Text] [Related]
14. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
Dale DC; Bolyard AA; Shannon JA; Connelly JA; Link DC; Bonilla MA; Newburger PE
Blood Adv; 2022 Jul; 6(13):3861-3869. PubMed ID: 35476051
[TBL] [Abstract][Full Text] [Related]
16. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
17. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia.
Freedman MH
Curr Opin Hematol; 1997 May; 4(3):217-24. PubMed ID: 9209840
[TBL] [Abstract][Full Text] [Related]
18. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
19. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
Lehrnbecher T
Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
